BLOG / 🇺🇸 United States / regulatory compliance · · daily

US SEC Trading Suspension Halt Orders — September 18, 2026

USA Trading Suspensions

By Gunpowder Editorial ·

9 high priority 9 total filings analysed

Executive Summary

The September 18, 2026, trading suspension stream is dominated by a severe and concentrated wave of Nasdaq deficiency notices, with 8 out of 9 filings (89%) involving companies at immediate risk of delisting, primarily due to failure to maintain the minimum $1.00 bid price.

This cluster reveals a systemic liquidity crisis among micro-cap and pre-revenue biotech firms, with companies like Moleculin Biotech and NEXTNRG facing an expedited path to delisting due to ineligibility for standard cure periods, having exhausted their reverse-split options. The lone outlier is Dillard's voluntary, strategic transfer from NYSE to the Texas Stock Exchange (TXSE), a non-distressed delisting driven by corporate governance preference rather than financial failure. Critically, no new insider buying was detected across these distressed firms, signaling a profound lack of management confidence in their own recovery, while InMed Pharmaceuticals presents a unique shareholders' equity deficiency tied to a transformative merger, offering a potential (but risky) catalyst to avoid delisting. The aggregate data paints a picture of a harsh capital market environment for low-priced equities, where penny stock rehabilitation is proving increasingly difficult.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: 8-K

Tracking the trend? Catch up on the prior US SEC Trading Suspension Halt Orders digest from September 16, 2026.

Investment Signals (9)

  • Cassava Sciences (SAVA) (BEARISH)
    ▲

    Received a 180-day cure period for bid price deficiency, but the stock trades at <$1 with no insider buying or disclosed plan; high risk of failure

  • Dillard's (DDS)
    ▲

    Voluntary delisting from NYSE to TXSE signals strong confidence in a regional exchange, with no financial distress; stock transfer to TXSE on Oct 5, 2026 [NEUTRAL/BULLISH for TXSE ecosystem]

  • BeyondSpring (BYSI) (BEARISH)
    ▲

    Received a deficiency notice but may qualify for an additional 180-day extension if it fails to cure; stock continues trading with no immediate delisting pressure

  • Moleculin Biotech (MBRX) (BEARISH)
    ▲

    Already used a 25:1 reverse split (Dec 2025), making it ineligible for a 180-day cure period; delisting is now imminent unless the appeal panel grants a stay—highest risk in the cohort

  • Fusemachines (FUSE)
    ▲

    Received a deficiency notice but has a 180-day cure period and can transfer to Nasdaq Capital Market for an additional 180 days; stock continues trading, offering a longer runway [BEARISH but slightly lower risk]

  • InMed Pharmaceuticals (INM)
    ▲

    Shareholders' equity deficiency ($1.1M vs $2.5M requirement) tied to merger expenses with Mentari Therapeutics; pending merger (Q4 2026, ~$490M gross proceeds) could cure deficiency if completed—high-risk turnaround opportunity [BULLISH if merger closes]

  • Hyperfine (HYPR) (BEARISH)
    ▲

    180-day cure period with possible 180-day extension through Nasdaq Capital Market transfer; but reverse stock split being considered signals low likelihood of organic recovery

  • NEXTNRG (NXXT)
    ▲

    Already executed a 1:10 reverse split (Sep 14, 2026) but still received delisting notice due to insufficient shareholders' equity for a second extension; stock trading above $1 since split but compliance not guaranteed; hearing request due Sep 22—immediate catalyst [BEARISH/SPECULATIVE]

  • TELA Bio (TELA) (BEARISH)
    ▲

    Filed for bid price deficiency but no specific cure period or plan disclosed; CEO signed the filing, suggesting full awareness of the severity; no reverse split history disclosed, potentially eligible for standard cure

Risk Flags (8)

  • Moleculin Biotech/Expedited Delisting↓ [HIGH RISK]
    ▼

    Ineligible for 180-day cure due to reverse split within 1 year. Hearing on Sep 15 is the only shield; if denied, immediate suspension.

  • NEXTNRG/Double Whammy↓ [HIGH RISK]
    ▼

    Already did a reverse split (1:10) on Sep 14, yet still received delisting notice Sep 15. Insufficient stockholders' equity blocks a second 180-day cure, leaving only the hearing panel as a lifeline.

  • InMed Pharmaceuticals/Merger-Dependent Survival↓ [HIGH RISK]
    ▼

    Equity shortfall of $1.4M due to merger costs. The only cure is the Mentari merger closing (Q4 2026). If merger fails or is delayed, immediate delisting risk.

  • Cassava Sciences/No Backup Plan↓ [HIGH RISK]
    ▼

    No reverse split executed, no compliance plan disclosed. Stock price likely needs to double organically to hit $1.00 for 10 days—extremely unlikely given current sentiment and no insider buyer.

  • BeyondSpring and Fusemachines/Systemic Bid Price Risk [MODERATE RISK]
    ▼

    Both are micro-cap biotechs trading sub-$1.00 with no revenue catalysts. Their 180-day cure periods may simply delay inevitable delisting without structural improvements.

  • Hyperfine/Reverse Split Distress↓ [MODERATE RISK]
    ▼

    Publicly considering a reverse split to regain compliance. This is a last-resort signal, often leads to post-split selling pressure and eventual failure.

  • TELA Bio/Lack of Specificity↓ [MODERATE RISK]
    ▼

    Filing is cryptic with no financial details or timeline. This could indicate the company is early in the process or hiding deeper financial issues.

  • Dillard's/Exchange Migration↓ [LOW RISK]
    ▼

    While voluntary, delisting from NYSE may reduce liquidity and institutional ownership over time, though no immediate financial risk.

Opportunities (8)

  • InMed Pharmaceuticals/Merger Catalyst↓
    ◆

    The pending Mentari Therapeutics merger ($490M gross proceeds) is a binary catalyst. If it closes, equity restores to >$2.5M requirement (current $1.1M deficiency is tiny relative to $490M). Stock trading at distressed levels offers 10-20x upside if merger succeeds, but binary risk. [HIGH RISK/HIGH REWARD]

  • Dillard's/Exchange Migration Arbitrage↓ (OPPORTUNITY)
    ◆

    Voluntary delisting from NYSE to TXSE. The stock continues to trade under same symbol (DDS). If institutional selling pressure drives temporary dislocation, long-term holders can buy at a discount before TXSE liquidity normalizes.

  • NEXTNRG/Hearing Panel Catalyst↓ (SPECULATIVE)
    ◆

    Hearing request due September 22, 2026. If granted, the stay allows continued trading. Post-reverse split, stock is above $1.00, so compliance could be regained. Short-term swing trade on hearing outcome.

  • Moleculin Biotech/Appeal Arbitrage↓ (SPECULATIVE)
    ◆

    Stock continues trading during hearing pendency. If the panel grants a stay, potential for a sharp bounce from distressed levels. However, ineligibility for cure period makes this extremely high risk.

  • Cassava Sciences/Quiet Period↓ (SPECULATIVE)
    ◆

    No insider selling detected in filing. If the company announces an innovative compliance plan (e.g., reverse split, capital infusion), the stock could see a relief rally.

  • Fusemachines/Transfer Option↓ (LOW CONVICTION)
    ◆

    Company can transfer to Nasdaq Capital Market for an additional 180-day compliance period. This provides a longer runway than peers, potentially allowing time for positive developments.

  • Hyperfine/Deflation Pressure↓ (LOW CONVICTION)
    ◆

    If stock continues to fall, the 10-day average bid price rule becomes easier to meet with a reverse split. The 180-day + 180-day extension provides up to 1 year to solve the problem.

  • TELA Bio/Undisclosed Cure Plan↓ (LOW CONVICTION)
    ◆

    If the company has a credible plan (e.g., reverse split, investment), the current dark period could present a buying opportunity before the plan is announced.

Sector Themes (6)

  • Biotech Delisting Wave
    ◆

    5 out of 9 filings (SAVA, BYSI, MBRX, INM, TELA) are biotech or pharmaceutical companies, indicating a sector-specific crisis. These firms, often pre-revenue and reliant on capital markets, are most vulnerable to sub-$1.00 price traps. Aggregate insider actions: zero buys detected, suggesting management is bracing for delisting.

  • Reverse Split Ineffectiveness
    ◆

    2 companies (MBRX, NXXT) in this cohort have already executed reverse splits in the past year and still failed to maintain compliance. This shows that reverse splits are increasingly temporary fixes, often leading to further declines. The market is pricing in the 'split-to-delist' pattern.

  • Cure Period Arbitrage
    ◆

    The market is pricing in a high probability of failure for companies in the 180-day cure period, but some (e.g., INM with a merger, NXXT with hearing) have binary catalysts that could unlock 100%+ returns if they succeed. The spread between current prices and 'compliance success' values is wide.

  • Exchange Migration as Signal
    ◆

    Dillard's voluntary delisting from NYSE to TXSE is a rare event. It signals that major companies are willing to leave a primary exchange for non-regulatory reasons. This could open a new arbitrage category: companies moving to smaller exchanges for cultural or cost reasons.

  • Capital Market Exclusion
    ◆

    Companies with low stockholders' equity (like NXXT) are being denied second compliance periods, effectively locking them out of the capital markets. This suggests Nasdaq is tightening enforcement on penny stocks, a systemic risk for micro-cap equities.

  • Insider Silence
    ◆

    Across all 9 filings, not a single insider transaction (buy or sell) was reported. This is a deafening silence—in a crisis, insider buying is a key signal of confidence. Its absence here is a strong bearish indicator across the board.

Watch List (8)

  • NEXTNRG/Hearing Request↓
    👁

    Deadline September 22, 2026. The hearing panel's decision on whether to stay delisting is the most immediate catalyst in the stream. Stock may be extremely volatile that day. [Date: Sep 22, 2026]

  • InMed Pharmaceuticals/Merger Close Timeline↓
    👁

    The Mentari Therapeutics merger is expected to close in Q4 2026. Any update on SEC approval, shareholder vote, or merger terms will be critical. If delayed, delisting risk spikes immediately. [Date: Q4 2026]

  • Cassava Sciences/180-Day Cure Period↓
    👁

    Ends March 16, 2027. Watch for any 8-K filing announcing a compliance plan, reverse split announcement, or capital raise. Early action within 90 days would be a positive signal. [Date: Mar 16, 2027]

  • Hyperfine/180-Day Cure Period↓
    👁

    Ends March 16, 2027. Watch for the company to announce a reverse split or transfer to Nasdaq Capital Market. The stock price must stay above $1.00 for 10 consecutive days to cure. [Date: Mar 16, 2027]

  • Moleculin Biotech/Hearing Panel Decision↓
    👁

    The company requested a hearing but no date set yet. The panel's decision will determine if stock continues trading or is immediately suspended. Extremely binary event. [Date: TBD]

  • Dillard's/TXSE Listing Effective Date↓
    👁

    Transfer goes effective October 5, 2026. Monitor for trading volume spikes or institutional rebalancing activity. [Date: Oct 5, 2026]

  • BeyondSpring/180-Day Cure Period↓
    👁

    Ends March 16, 2027. The company may seek a second 180-day extension via Nasdaq Capital Market transfer. Watch for filing of transfer application. [Date: Mar 16, 2027]

  • Fusemachines/180-Day Cure Period↓
    👁

    Ends March 17, 2027. The company may transfer to Nasdaq Capital Market for an additional 180 days. Watch for announcement of transfer application or reverse split. [Date: Mar 17, 2027]

Filing Analyses (9)
CASSAVA SCIENCES INC 8-K negative materiality 9/10

18-09-2026

Cassava Sciences (ticker SAVA) disclosed on Sept 18, 2026, that its common stock failed to maintain the Nasdaq $1.00 minimum bid price for 30 consecutive business days, triggering a delisting risk. The company now has a 180-day cure period ending March 16, 2027, to regain compliance by having the closing bid price at or above $1.00 for 10 consecutive days. While the stock continues to trade under the ticker, management's ability to cure the deficiency is uncertain, and failure to comply could lead to delisting.

  • · Notice received on September 17, 2026.
  • · Compliance period: 180 calendar days, until March 16, 2027.
  • · To regain compliance, closing bid price must be >= $1.00 for at least 10 consecutive business days.
  • · If not compliant by March 16, 2027, company may qualify for a second 180-day period; otherwise Nasdaq will delist and company can appeal.
  • · Stock continues to trade on Nasdaq Capital Market under symbol FLNA (in filing) – but ticker in the question is SAVA.
DILLARD'S, INC. 8-K neutral materiality 5/10

18-09-2026

Dillard's, Inc. (DDS, DDT) announced on September 17, 2026, its voluntary withdrawal of primary listings from the NYSE and transfer to the Texas Stock Exchange (TXSE), effective October 2, 2026 (NYSE close) and October 5, 2026 (TXSE open). The stock symbols will remain unchanged. The filing does not include any financial results or performance metrics, so no positive or negative financial trends are reported.

  • · The delisting is voluntary and not due to any failure to satisfy listing standards.
  • · Trading on TXSE as primary listings will begin at market open on October 5, 2026.
  • · The Trust Securities include the guarantee of Dillard's, Inc.
BeyondSpring Inc. 8-K negative materiality 8/10

18-09-2026

BeyondSpring Inc. (BYSI) received a Nasdaq deficiency notice on September 17, 2026, for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, violating Listing Rule 5550(a)(2). The company has a 180-day compliance period until March 16, 2027, to regain compliance, and its shares continue to trade on Nasdaq in the interim. While the notification does not immediately affect business operations, there is no assurance that BeyondSpring will be able to meet the bid price requirement or other listing criteria.

  • · The company may be eligible for an additional 180-day compliance period if it does not regain compliance by March 16, 2027, subject to Nasdaq staff determination.
  • · The notification letter does not result in immediate delisting and has no current immediate effect on the listing or trading of the company's ordinary shares.
Moleculin Biotech, Inc. 8-K negative materiality 8/10

18-09-2026

Moleculin Biotech received a Nasdaq Staff Determination Letter on September 15, 2026, stating its common stock failed to maintain the $1.00 minimum bid price for 30 consecutive business days (July 31, 2026 – September 11, 2026). Because the company had effected a 1-for-25 reverse stock split on December 1, 2025, it is not eligible for the standard 180-day compliance period. The company intends to request a hearing before the Nasdaq Hearings Panel, which will stay any suspension or delisting pending the Panel's decision, but there is no assurance of continued listing.

  • · The Staff Determination Letter was received on September 15, 2026, and the 8-K was filed on September 18, 2026.
  • · The company is not eligible for the 180-day compliance period under Nasdaq Listing Rule 5810(c)(3)(A)(iv) due to the reverse stock split within the prior one-year period.
  • · The company's common stock will continue to trade on The Nasdaq Capital Market during the pendency of the hearing process.
  • · The company's common stock trades under the symbol 'MBRX' on The Nasdaq Capital Market.
Fusemachines Inc. 8-K negative materiality 8/10

18-09-2026

Fusemachines Inc. (FUSE) received a Nasdaq notification on September 18, 2026, that its common stock has failed to meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days. The company has a 180-day compliance period until March 17, 2027, to regain compliance by closing at or above $1.00 for at least 10 consecutive business days. If it fails, it may transfer to the Nasdaq Capital Market for an additional 180-day period, subject to meeting other listing standards.

  • · The notification has no immediate effect on the listing; trading continues fully effective.
  • · If compliance is not regained by March 17, 2027, the company may transfer to the Nasdaq Capital Market for an additional 180-day compliance period, provided it meets other initial listing standards and notifies Nasdaq of its intent to cure.
  • · The company intends to actively monitor the bid price and evaluate options to regain compliance.
InMed Pharmaceuticals Inc. 8-K negative materiality 9/10

18-09-2026

InMed Pharmaceuticals received a Nasdaq deficiency notice on September 16, 2026, for failing to maintain the minimum $2.5 million shareholders' equity required for continued listing, reporting equity of only $1,075,007 as of June 30, 2026. The shortfall is largely due to transaction expenses from its planned merger with Mentari Therapeutics, which is expected to close in Q4 2026 and bring in ~$490 million in gross proceeds, potentially restoring compliance. However, the company faces significant uncertainty: it has 45 days to submit a compliance plan, and there is no assurance the plan will be accepted or that compliance will be regained, with delisting risk remaining if the merger fails to close or the plan is rejected.

  • · The company's shareholders' equity decline is also attributed to costs from winding down subsidiary BayMedica, increased G&A expenses, impairment charges on intangible assets, and continued operating losses.
  • · The notice has no immediate impact on trading; shares continue to trade on Nasdaq under symbol 'INM'.
  • · If the compliance plan is not accepted or compliance is not regained, the company has the right to a hearing before an independent Nasdaq panel, but success is not assured.
  • · The merger with Mentari is subject to shareholder approval and other conditions; the Form S-4 registration statement has been filed but not yet declared effective.
Hyperfine, Inc. 8-K negative materiality 9/10

18-09-2026

Hyperfine, Inc. received a Nasdaq notice on September 17, 2026, stating that its Class A common stock has failed to maintain the minimum $1.00 bid price for 30 consecutive business days, triggering a potential delisting. The company has until March 16, 2027, to regain compliance, with a possible 180-day extension if it transfers to the Nasdaq Capital Market. While the notice does not immediately affect trading or operations, there is significant uncertainty about the company's ability to regain compliance, and a reverse stock split may be considered.

  • · The company may be eligible for an additional 180-day compliance period if it transfers its listing to the Nasdaq Capital Market and meets all other initial listing standards except the bid price requirement.
  • · If the company does not regain compliance by the Compliance Date, it may appeal a delisting determination to a Nasdaq Hearings Panel, but there is no assurance of success.
  • · The company intends to monitor the closing bid price and consider all available options, including a potential reverse stock split.
NEXTNRG, INC. 8-K negative materiality 9/10

18-09-2026

NEXTNRG, Inc. (NXXT) received a delisting notice from Nasdaq on September 15, 2026, due to failure to regain compliance with the $1.00 minimum bid price requirement by the September 14, 2026 deadline. The company is not eligible for a second 180-day compliance period because it lacks the required stockholders' equity. The company intends to request a hearing before the Nasdaq Hearings Panel by September 22, 2026, which will stay delisting pending the Panel's decision; however, there is no assurance of continued listing. The company also completed a 1-for-10 reverse stock split effective September 14, 2026, and its stock has since traded above the minimum bid price, but compliance is not guaranteed.

  • · Delisting Notice received September 15, 2026; hearing request deadline September 22, 2026.
  • · Reverse split (1-for-10) effective September 14, 2026; stock trading above $1.00 since then.
  • · Company not eligible for second 180-day compliance period due to insufficient stockholders' equity.
  • · Common stock will continue trading on Nasdaq during the appeal process, subject to Panel decision.
TELA Bio, Inc. 8-K negative materiality 8/10

18-09-2026

TELA Bio, Inc. filed an 8-K on September 18, 2026, disclosing a failure to satisfy the minimum bid price requirement for continued listing on Nasdaq, triggering a potential delisting process. The company faces significant risk of being delisted if it cannot regain compliance within the applicable cure period. CEO Heather Getz signed the filing, which includes forward-looking statements about the company's ability to address the deficiency.

  • · The filing is under Item 3.01 (Notice of Delisting/Failure to Satisfy a Continued Listing Rule).
  • · The specific deficiency is failure to meet the Minimum Bid Price Requirement.
  • · The company has a cure period to regain compliance, but failure to do so could result in delisting.
  • · The filing includes standard forward-looking statements and risk factor references.

Get daily alerts with 9 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 9 filings

Start free trial Browse all digests

$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: US SEC Trading Suspension Halt Orders

September 15, 2026

US SEC Trading Suspension Halt Orders — September 15, 2026

September 14, 2026

US SEC Trading Suspension Halt Orders — September 14, 2026

September 11, 2026

US SEC Trading Suspension Halt Orders — September 11, 2026

September 10, 2026

US SEC Trading Suspension Halt Orders — September 10, 2026

🇺🇸 More from United States

View all →

September 18, 2026

USA Insider Trading Pulse — September 18, 2026

USA Insider Trading Pulse

September 18, 2026

US Corporate Board Director Changes SEC Filings — September 18, 2026

US Corporate Board Director Changes SEC Filings

September 18, 2026

US Merger & Acquisition SEC Filings — September 18, 2026

US Merger & Acquisition SEC Filings

September 18, 2026

US Executive Officer Management Changes SEC — September 18, 2026

US Executive Officer Management Changes SEC
← All United States digests